Imagenomix Corp will receive computing credits and technical expertise from Amazon Web Services to further validate the IGX Predict AI Assay for launch with pharma partners to develop cancer mutational cancer screening for targeted therapies.
New York, NY 6/1/24 — Imagenomix today announced that it has been selected as part of the Amazon Web Services (AWS) Health Equity Initiative, a $60 million, three-year commitment, supporting organizations that are developing solutions to advance health equity.
The support from AWS will advance Imagenomix’s efforts to provide all cancer patients with access to advanced genomic AI cancer screening. We strive to empower every patient with timely and affordable solutions, ensuring no patient is left behind in the fight against cancer.
By leveraging our proprietary AI and an extensive dataset, the Imagenomix AI platform predicts driver mutations for treatment or clinical trials within minutes, using proprietary computational models. Our AI-based genomic screening platform will provide access to therapeutics for every cancer patient, saving time, money, and lives for patients, hospitals, and clinical trials alike. With the support of AWS, Imagenomix will grow and scale our IGX Predict platform to help genomically untested patients in every country, utilizing AWS’s robust computing credits and technical expertise to enhance our capabilities and expand our reach globally.
“AWS believes individual health outcomes should not depend on socioeconomic status, race, ethnicity, or neighborhood,” said Danielle Morris, Global Health Equity Lead at AWS “Cloud technology can help address inequities in global health to expand access to the services people need to live longer, healthier lives–no matter who they are or where they live. Through the AWS Health Equity Initiative, we look forward to helping Imagenomix and other organizations worldwide use the power of cloud computing to advance health equity and improve health outcomes.”
Through the initiative, AWS offers AWS credits and customized technical expertise to selected organizations around the world that want to use AWS services to improve health outcomes and health equity in any of the following areas: 1) Increasing access to high-quality, culturally responsive health services; 2) Increasing access to responsive social and community support; and 3) Mitigating the impact of climate change on health and quality of life.
To learn more about the AWS initiative, visit https://aws.amazon.com/health/health-equity.
About Imagenomix Corp
Headquarters: New York, NY
Leadership Team:
- Travis Wold, MBA: CEO
- Dr. Snuderl: Co-Founder
- Dr. Tsrigos: Co-Founder
- Dr. Orringer: Co-Founder
About Us:
Imagenomix Corp (IGX) is at the forefront of innovation in the biotechnology sector, specializing in the rapid detection of cancer-causing mutations using artificial intelligence. Founded as a spin-off from New York University, IGX is driven by a mission to revolutionize cancer diagnostics and enhance patient outcomes through cutting-edge technology.
Core Technology:
IGX leverages its proprietary AI algorithms to analyze Hematoxylin and Eosin (H&E) stained slides, a standard method in pathology, for the swift identification of genetic mutations associated with cancer. This groundbreaking approach offers significant advantages in speed and accuracy compared to traditional diagnostic methods.
Patents:
IGX holds several patents related to the detection of mutations from H&E slides, positioning the company as a leader in AI-driven cancer diagnostics.
Products and Services:
- Diagnostic Services: AI-based analysis of H&E slides and fresh tissue for the detection of cancer-causing mutations.
- Partnerships: Collaborations with pharmaceutical companies to enhance drug development and personalized medicine through precise mutation detection.
- IT Reporting System: Developing a robust reporting platform to provide clients with comprehensive and actionable diagnostic insights.
Mission and Vision:
Our mission is to revolutionize cancer diagnostics through the application of advanced AI technologies, providing faster, more accurate, and more reliable results. We envision a future where cancer is detected early and treated more effectively, significantly improving patient outcomes and survival rates.
Growth and Expansion:
With a strong foundation in research and innovation, IGX is poised for rapid growth. The current fundraising efforts are aimed at scaling operations, enhancing technological capabilities, and expanding our market reach to solidify our position as a leader in the AI-driven diagnostics industry.
Contact Information:
For more information about Imagenomix Corp,, our services, or partnership opportunities, please visit our website or email us at: [email protected]